Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.
Oncology
News and Features
Ulenistamab targets pancreatic adenocarcinoma upregulated factor, a tumor-specific protein.
Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.
Polypharmacy tied to increased risk for adverse treatment outcomes, such as toxicity and early treatment discontinuation.
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF.
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
In subgroup analyses, lower risk was seen with cumulative dosage of 401mg or greater, or with therapy duration of 5 years or longer.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation.
Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma
Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.
Less high-grade disease recurrence and lower treatment discontinuation seen with gemcitabine and docetaxel versus bacillus Calmette-Guérin
Event-free survival longer for those receiving neoadjuvant and adjuvant pembrolizumab versus adjuvant pembrolizumab only
The panel reviewed data from the randomized, double-blind, placebo-controlled phase 3 POLARIX trial.
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.
The updates require facilities to notify patients regarding the density of their breasts, and strengthen the FDA’s oversight of facilities.